Delek US Holdings has seen its shares surge nearly 200% over the past year, driven by regulatory relief from EPA small refinery exemptions and increased crack spreads due to geopolitical disruptions. The company maintains a strong financial position with $615 million in cash and $889 million in debt, plus a valuable stake in DKL. Analysts estimate a fair value of $53 per share, suggesting about 20% upside from current levels, supported by ongoing share buybacks. While no longer rated a "Strong Buy" after a 50% rally, Delek US Holdings remains a "Buy" with potential to exceed $50 per share.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
